Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 Recruiting
21 enrolled
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Phase 3 Recruiting
150 enrolled
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Phase 1 Recruiting
33 enrolled
MK-3475-D20
Phase 1/2 Recruiting
176 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 Recruiting
217 enrolled
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Recruiting
200 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1 Recruiting
20 enrolled
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 Recruiting
44 enrolled
24CT015
Phase 1 Recruiting
33 enrolled
A Study of Enasidenib in People With T-Cell Lymphoma
Phase 2 Recruiting
25 enrolled
Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
Recruiting
3,000 enrolled
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 Recruiting
70 enrolled
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 Recruiting
48 enrolled
VIPER101
Phase 1 Recruiting
30 enrolled
Tissue Repository: CTCL Collection Protocol
Recruiting
400 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 Recruiting
127 enrolled
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Phase 2 Recruiting
46 enrolled
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
46 enrolled
Study of Tazemetostat in Lymphoid Malignancies
Phase 1 Recruiting
30 enrolled
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 Recruiting
51 enrolled
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Phase 2 Recruiting
50 enrolled
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2 Recruiting
56 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Phase 1/2 Recruiting
290 enrolled
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Recruiting
200 enrolled
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/2 Recruiting
36 enrolled
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Phase 1 Recruiting
108 enrolled
A Registry for People With T-cell Lymphoma
Recruiting
1,000 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase 1/2 Recruiting
85 enrolled
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/2 Recruiting
36 enrolled
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
Phase 1 Recruiting
48 enrolled
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Phase 1/2 Recruiting
180 enrolled
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Phase 2 Recruiting
32 enrolled